Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Monsanto Co. -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (1331)	2/23/1999 9:01:00 PM
From: Dan Spillane	Read Replies (1) \| Respond to of 2539

Wow, something new about Celebrex...I wonder if they will eventually identify the platelet (thinning) effects of aspirin as a co-factor in GI and other bleeding deaths. Makes you wonder, many folks die of bleeding from an ulcer...it's not only the perforation, but the loss of blood which is exacerbated by thinning. Maybe there is another benefit of Celebrex that we aren't immediately aware of -- for those people subject to any disease or injury which would be worsened by thinning? *** Dr. Isakson: One of the advantages of Celebrex is its lack of the platelet effect. There wouldn't necessarily be a concern with taking Celebrex and any of those agents. With Coumadin, there are additional potential reactions, both by displacement of protein binding as well as interference with metabolism. Therefore, we conducted a drug interaction study between Celebrex and Coumadin, or warfarin, and found no adverse effects whatsoever. We have not conducted any studies directly related to heparin.